GH - Cancer Test Firm Guardant Health Posts Smaller Than Expected Q3 Loss Lifts Annual Sales Outlook | Benzinga
Guardant Health Inc (NASDAQ: GH) reported Q3 revenue of $143 million, up 22% Y/Y, beating the consensus of $137.37 million.
Precision oncology revenue grew 31%, driven predominantly by increased clinical testing volume and biopharma sample volume, which grew 35% and 11%, respectively.
The company reported 43,900 tests to clinical customers and 7,500 tests to biopharmaceutical customers in the ...